View Financial HealthPasithea Therapeutics 配当と自社株買い配当金 基準チェック /06Pasithea Therapeutics配当金を支払った記録がありません。主要情報n/a配当利回り-305.0%バイバック利回り総株主利回り-305.0%将来の配当利回りn/a配当成長n/a次回配当支払日n/a配当落ち日n/a一株当たり配当金n/a配当性向n/a最近の配当と自社株買いの更新Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more updateすべての更新を表示Recent updatesPasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21Pasithea Therapeutics Provides Outlook on Pas-004 Clinical Programs and Data Release TimelinesJan 13Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.Nov 27Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more updateNew minor risk - Share price stability Nov 20Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08New major risk - Financial position Aug 15Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31Pasithea Therapeutics Corp., Annual General Meeting, Sep 03, 2025Jul 16Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29Pasithea Therapeutics Appoints James Lee to Scientific Advisory BoardJun 11Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering.May 01Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13New major risk - Shareholder dilution Mar 26New major risk - Financial position Mar 25New minor risk - Share price stability Feb 05Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20New major risk - Financial position Nov 15Pasithea Therapeutics Corp. announced that it has received $5.000003 million in fundingOct 01Pasithea Therapeutics Corp. announced that it expects to receive $5.000003 million in fundingSep 27Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03New minor risk - Share price stability Jul 30Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15Pasithea Therapeutics Corp., Annual General Meeting, Jun 26, 2024May 17Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02New major risk - Financial position Nov 20Pasithea Therapeutics Corp. Selects PAS-003 Lead Development CandidateNov 10Pasithea Therapeutics Corp., Annual General Meeting, Nov 29, 2023Oct 27High number of new and inexperienced directors Oct 20Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more updateNew major risk - Share price stability Jul 21Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26Concord IP2 Recommends Stockholders to Vote for Boardroom Change at Pasithea TherapeuticsDec 08Price target decreased to US$2.30 Nov 16Less than half of directors are independent Nov 16Concord IP2 Ltd Files a Lawsuit Against the Directors of Pasithea Therapeutics Corp Nov 02Camac Partners Comments on Pasithea Therapeutics’ Acquisition of AlloMek TherapeuticsOct 14Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more updateCamac Partners LLC Sends a Letter to Pasithea Therapeutics CorpSep 30Less than half of directors are independent Sep 23Pasithea Therapeutics Corp. Appoints Alfred J. Novak to Its Board of DirectorsSep 21Pasithea Therapeutics Corp. Appoints Dr. Merit Cudkowicz to its Scientific Advisory BoardSep 16Camac Partners Provides Information to Shareholders of Pasithea TherapeuticsSep 09+ 1 more updateCamac Partners Urges Stockholders of Pasithea Therapeutics to Vote to Call Special MeetingAug 26Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06Concord IP2 Ltd Nominates Candidates to the Board of Pasithea Therapeutics CorpJul 29We're Not Very Worried About Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn RateJul 21Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02Concord IP2 Ltd Provides Information to Shareholders of Pasithea Therapeutics CorpJun 28Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 17Stanley Gloss, the Chief Financial Officer of Pasithea Therapeutics Corp., Passes AwayJun 11Concord IP2 Ltd Sends a Letter to Pasithea Therapeutics CorpJun 02Pasithea Therapeutics Corp., Annual General Meeting, Jun 23, 2022May 14Less than half of directors are independent Apr 27Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06Pasithea Therapeutics Appoints Daniel Weinberger to Its Scientific Advisory BoardFeb 10Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04Pasithea Therapeutics Corp. announced that it has received $30.38 million in fundingNov 30Pasithea Therapeutics Corp. announced that it expects to receive $30.38 million in fundingNov 26Pasithea Therapeutics Adds Esketamine Nasal Spray to Its Clinic Offerings in the U.KNov 24決済の安定と成長配当データの取得安定した配当: KTTAの 1 株当たり配当が過去に安定していたかどうかを判断するにはデータが不十分です。増加する配当: KTTAの配当金が増加しているかどうかを判断するにはデータが不十分です。配当利回り対市場Pasithea Therapeutics 配当利回り対市場KTTA 配当利回りは市場と比べてどうか？セグメント配当利回り会社 (KTTA)n/a市場下位25% (US)1.4%市場トップ25% (US)4.2%業界平均 (Biotechs)2.6%アナリスト予想 (KTTA) (最長3年)n/a注目すべき配当: KTTAは最近配当金を報告していないため、配当金支払者の下位 25% に対して同社の配当利回りを評価することはできません。高配当: KTTAは最近配当金を報告していないため、配当金支払者の上位 25% に対して同社の配当利回りを評価することはできません。株主への利益配当収益カバレッジ: KTTAの 配当性向 を計算して配当金の支払いが利益で賄われているかどうかを判断するにはデータが不十分です。株主配当金キャッシュフローカバレッジ: KTTAが配当金を報告していないため、配当金の持続可能性を計算できません。高配当企業の発掘7D1Y7D1Y7D1YUS 市場の強力な配当支払い企業。View Management企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/03 10:40終値2026/05/01 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Pasithea Therapeutics Corp. 1 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Sara NikH.C. Wainwright & Co.
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update
Pasithea Therapeutics Corp Announces Grant of Rare Pediatric Disease Designation by FDA to Pas-004 for Treatment of Neurofibromatosis Type 1Apr 21
Pasithea Therapeutics Corp Announces Grant of Fast Track Designation by Fda to Pas-004 for Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas Causing Significant MorbidityApr 01
Pasithea Therapeutics Corp. Receives Notice of Non-Compliance with Nasdaq Minimum Bid Price Listing RuleFeb 21
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $59.934847 million.Dec 02
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) DataNov 25
Pasithea Therapeutics Corp. Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 PatientsNov 22+ 1 more update
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $10 million.Nov 19
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Site At University of Alabama At Birmingham for Ongoing Phase 1/1B Trial of Pas-004 in Adult Nf1 PatientsNov 06
Pasithea Therapeutics Corp. Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 PatientsSep 16
Pasithea Therapeutics Corp. Announces Enrollment of Cohort 2 Following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsSep 08
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 PatientsJul 31
Pasithea Therapeutics Receives Nasdaq Non-Compliance Notice Regarding Minimum Bid Price RequirementJun 29
Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 At the ASCO Annual Meeting 2025Jun 02
Pasithea Therapeutics Announces Preclinical Data That Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market DiseasesMay 20
Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial SiteMay 15
Pasithea Therapeutics Corp. has completed a Follow-on Equity Offering in the amount of $4.999522 million.May 09
Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004May 08
Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer PatientsApr 30
Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual MeetingApr 24
Pasithea Therapeutics Corp. Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerApr 13
Pasithea Therapeutics Announces Positive Safety Review Committee (Src) Recommendation from Its Ongoing Phase 1 Clinical Trial of Pas-004 in Advanced CancerFeb 05
Pasithea Therapeutics Corp. has filed a Follow-on Equity Offering in the amount of $2.076 million.Nov 27
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerNov 20
Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory BoardSep 03
Pasithea Therapeutics Corp. Announces Completion of Enrollment and Initial Dosing of Cohort 2 Following Positive Safety Review Committee Recommendation for PAS-004 in Ongoing Phase 1 Clinical TrialJun 15
Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated CancersApr 25
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004Feb 14
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) PositionJan 10
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer PatientsJan 02
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery ProgramAug 02
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) announces an Equity Buyback for 5,700,000 shares, for $4 million.Jul 23+ 1 more update
Lucy Scientific Discovery Inc. (NasdaqCM:LSDI) made a proposal to acquire Pasithea Therapeutics Corp. (NasdaqCM:KTTA) for $22.2 million.Jun 07
Pasithea Therapeutics Receives A Written Notice from Nasdaq Regarding Minimum Bid Price RequirementJan 26
Pasithea Therapeutics Corp. (NasdaqCM:KTTA) acquired AlloMek Therapeutics, LLC from Integral Biosciences Private Limited, Innovation Pathways LLC, Shakti BioResearch LLC and others for $11.3 million.Oct 13+ 1 more update
Pasithea Therapeutics Corp. Announces Results of Preclinical Study Demonstrating Tolerizing Vaccine Efficacy in Relapsing-Remitting Model of Multiple SclerosisAug 12
Concord Investment Partners Ltd Urges Stockholders of Pasithea Therapeutics Corp to Call Special MeetingAug 06
Concord IP2 Ltd Files Solicitation Statement to Call a Special Meeting of Stockholders of Pasithea Therapeutics CorpJul 02
Here's Why We're Not At All Concerned With Pasithea Therapeutics' (NASDAQ:KTTA) Cash Burn SituationApr 06
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple SclerosisFeb 04
